January 21st 2021, 7:00pm
“Along with a tolerable safety profile and supportive quality of life, these final efficacy results demonstrate the clinical benefit of (Tibsovo) in (previously treated patients with IDH1-mutant cholangiocarcinoma), for which there is an urgent need for new therapies,” said an expert from Massachusetts General Hospital, who presented the data.
January 19th 2021, 7:00pm
“This is the longest survival seen in a phase 3 study of advanced liver cancer,” lead study author Dr. Richard S. Finn, of the UCLA Jonsson Comprehensive Cancer Center, said in a virtual presentation of the data.
January 14th 2021, 10:30pm
Patients with hepatocellular carcinoma who live in low-income and rural households are less likely to receive high quality care and therefore are more likely to be diagnosed with an advanced stage cancer.
January 12th 2021, 7:00pm
Over the last 30 years, cases of childhood liver cancer have increased in the United States, Australia and a Canadian province.
January 7th 2021, 2:00pm
A roundup of liver cancer news and updates that occurred in 2020 patients with cancer may have missed.
December 17th 2020, 9:04pm
A clinical research coordinator discusses how patients with cholangiocarcinoma can get involved in clinical trials, such as the phase 3 PROOF trial, as well as what they should know once they are enrolled.
December 10th 2020, 4:00pm
This week on the “CURE® Talks Cancer” podcast, we spoke with renowned street artist James Cochran about one of his art projects that was commissioned to symbolize the creativity and commitment of those who work tirelessly to eradicate cancer.
December 9th 2020, 4:00pm
Street artist James Cochran gives CURE® an inside look at his newest project: a piece of art he created by applying 50,000 small dots of paint to a canvas using a lab pipette. It will be displayed in the Institute of Cancer Research’s Centre for Cancer Drug Discovery as a symbol of the creativity and commitment of the scientists who work every day to eradicate cancer.
November 2nd 2020, 10:00pm
Results of this trial led to an accelerated FDA approval of Opdivo (nivolumab) and Yervoy (ipilimumab) in March to treat this specific patient population.
October 6th 2020, 1:00pm
Overall survival was better with hepatic arterial infusion chemotherapy compared with transarterial chemoembolization, according to phase 3 study findings.
5 Recent COVID-19 News and Updates That Patients With Cancer May Have Missed
FDA Approves Cabometyx-Opdivo For Metastatic RCC Treatment
Novel Therapy Granted Priority Review By FDA for Treatment of Anal Cancer Subset
COVID-19 'Retired' Me, But Now I Can Reach For My Life Goals
